Navigation Links
Champions Oncology Reports Financial Results for the Year Ended April 30, 2012

n operating activities(5,227)(54)Cash flows from investing activities:  Purchases of and proceeds from sales of property and equipment


(84)Net cash used in investing activities:(519)(84)Cash flows from financing activities:  Private placement of common shares and warrants (net of $305 in offering costs)


9,095  Purchase of treasury stock


(1,033)  Proceeds from exercise of options and warrants


21Net cash provided by financing activities:978,083Exchange rate effect on cash and cash equivalents


(60)Increase (decrease) in cash and cash equivalents


7,885Cash and cash equivalents, beginning of year10,4572,572Cash and cash equivalents, end of year$4,754$10,457Contact:
Susan Foreman
410-369-0365 X140

SOURCE Champions Oncology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
2. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
3. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
4. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
5. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
6. Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
7. Prosperous Agriculture Reports Outstanding Sales Result for First Half of 2012
8. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
9. GeneLink Reports First Quarter 2012 Financial Results
10. Genesis Biopharma Mentioned Favorably in BioMedReports Article
11. Vermillion Reports First Quarter 2012 Results
Post Your Comments:
(Date:8/28/2014)...  Next month, executives from clinical trial marketing firm BBK ... with Patient-Centered Clinical Trials 2014 , to be held ... , September 4-5. Patient recruitment experts Bonnie A. Brescia ... will share insights on the benefits of employing an effective ... from media to mobile apps – can be used to ...
(Date:8/28/2014)... Exciting new work by a Florida State University ... that can take your temperature, emit white light, and ... the molecule looks like a butterfly. , Biwu Ma, ... Engineering in the FAMU-FSU College of Engineering, created the ... has continued to discover that his creation has many ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 PrimeSource ... construction materials, selected SoundConnect to support ... cloud based audio and web conferencing platform GlobalMeet ... support PrimeSource’s employees’ needs. SoundConnect delivers award ... , PrimeSource Building Products will be utilizing ...
(Date:8/27/2014)... TX (PRWEB) August 27, 2014 Green ... million in Series B funding and secured Otter Capital ... investment capital will accelerate commercialization of GGI’s Agriplier™ technology, ... crop types. , “Since our first meeting, we ... to the biological product space,” said Alan Sobba, President ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... Ortho Biotech is announcing,that it is voluntarily recalling one manufacturing lot ... of a,small number of vials upon post-manufacturing inspection. No other lot ... lot,P114942A in the following packaging configurations were distributed between,April 15, 2008 ... NDC Description ...
... Replidyne, Inc.,(Nasdaq: RDYN ) today announced its financial results ... Replidyne reported a net loss of $18.7 million for ... basic and diluted common share of $0.69,per share, compared to ... or $1.65 per common share on a fully diluted basis, ...
... Sangamo BioSciences,Inc. (Nasdaq: SGMO ) announced today ... update on the progress of Sangamo,s ZFP,Therapeutic development programs ... p.m. (ET) on Tuesday, August 12, 2008, at the ... presentation will be webcast live and may be accessed ...
Cached Biology Technology:Ortho Biotech Announces Nationwide Voluntary Recall of Procrit(R) (Epoetin Alfa) Lot Number P114942A 2Replidyne Announces Second Quarter 2008 Results From Operations 2Replidyne Announces Second Quarter 2008 Results From Operations 3Replidyne Announces Second Quarter 2008 Results From Operations 4Replidyne Announces Second Quarter 2008 Results From Operations 5Replidyne Announces Second Quarter 2008 Results From Operations 6Replidyne Announces Second Quarter 2008 Results From Operations 7Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference 2
(Date:8/28/2014)... 28, 2014) Researchers at the University of Minnesota ... dystrophy (FSHD) to be used for muscle regeneration research ... therapies for FSHD. , The research is published in ... . , There is no treatment for FSHD, which ... type of muscular dystrophy. FSHD is an unusual genetic ...
(Date:8/28/2014)... for delivering compounds that could positively impact ... may be possible, thanks to researchers in ... semi-soft vaginal suppository made from the seaweed-derived ... antiviral drug Tenofovir provides a woman-initiated, drug-delivery ... of sexually transmitted infections during unprotected heterosexual ...
(Date:8/28/2014)... kilometres of new roads will be built worldwide by ... last wildernesses, where they bring an influx of destructive ... ambitious study has created a ,global roadmap, for prioritising ... the competing demands of development and environmental protection. , ... estimates that natural importance of ecosystems and a ,road-benefits, ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... unprecedented decade-long study of apex predators in the Pacific ... species than previously thought, unknown relationships between other species, ... of most of these sea creatures. The field ... looked at 23 species from 2000-09 and included ...
... competing in an international pool of universities, corporations ... Awards in this year,s contest, and were cowinners of ... year to researchers whom its editors and independent judging ... advances in applied technologies. The awards, with their ...
... June 22, 2011 Los Alamos National Laboratory scientists have ... as the "Oscars of Invention" by the Chicago Tribune, ... of the past year. The winning Laboratory technologies include ... spacer fluid for oil wells that shrinks when heated, ...
Cached Biology News:Decade-long study of Pacific predators shows importance of biological 'hotspots' 2Decade-long study of Pacific predators shows importance of biological 'hotspots' 3Sandia captures 4 R&D 100 Awards 2Sandia captures 4 R&D 100 Awards 3Los Alamos National Laboratory earns 3 R&D 100 Awards 2Los Alamos National Laboratory earns 3 R&D 100 Awards 3
... 'A New Concept in Microarrays: Biomedical Photometrics ... technologies GmbH (Jena, Germany) have collaborated to ... CLONDIAG ArrayTube System. The DNAscope AT ... The new DNAscope AT automatically reads up ...
Complement factor B (human)...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
... Buffer was designed to meet the high ... sequencing labs. As a primary manufacturer and ... sequencing community Sigma has the know how ... buffer needs. Scientists at Sigma have taken ...
Biology Products: